Stifel Nicolaus Increases Disc Medicine (NASDAQ:IRON) Price Target to $94.00

Disc Medicine (NASDAQ:IRON - Free Report) had its price target lifted by Stifel Nicolaus from $90.00 to $94.00 in a research note released on Friday,Benzinga reports. They currently have a buy rating on the stock.

Other equities analysts have also recently issued reports about the stock. Raymond James raised shares of Disc Medicine from an "outperform" rating to a "strong-buy" rating and raised their price target for the stock from $66.00 to $110.00 in a research note on Monday, November 4th. Scotiabank increased their price objective on Disc Medicine from $70.00 to $73.00 and gave the company a "sector outperform" rating in a report on Wednesday. Cantor Fitzgerald restated an "overweight" rating and set a $85.00 target price on shares of Disc Medicine in a report on Tuesday, October 15th. Morgan Stanley raised Disc Medicine from an "equal weight" rating to an "overweight" rating and set a $85.00 price target for the company in a research note on Tuesday, November 5th. Finally, HC Wainwright restated a "buy" rating and set a $118.00 target price on shares of Disc Medicine in a research note on Tuesday. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $88.90.

Disc Medicine Price Performance

IRON traded up $0.46 during mid-day trading on Friday, hitting $57.45. The stock had a trading volume of 727,610 shares, compared to its average volume of 265,981. Disc Medicine has a 1-year low of $25.60 and a 1-year high of $77.60. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of -14.43 and a beta of 0.75. The stock's fifty day simple moving average is $62.62 and its 200-day simple moving average is $53.79.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($1.04) by $0.15. As a group, research analysts expect that Disc Medicine will post -4.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director William Richard White sold 1,957 shares of the business's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $64.63, for a total value of $126,480.91. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Rahul Khara sold 7,500 shares of Disc Medicine stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $62.75, for a total value of $470,625.00. Following the completion of the sale, the insider now owns 14,035 shares of the company's stock, valued at approximately $880,696.25. The trade was a 34.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 85,758 shares of company stock valued at $5,400,990 over the last 90 days. 4.24% of the stock is owned by insiders.

Institutional Investors Weigh In On Disc Medicine

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Amalgamated Bank lifted its position in shares of Disc Medicine by 76.9% during the second quarter. Amalgamated Bank now owns 568 shares of the company's stock valued at $26,000 after purchasing an additional 247 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Disc Medicine by 45.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company's stock worth $54,000 after buying an additional 337 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Disc Medicine by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,310 shares of the company's stock worth $400,000 after buying an additional 593 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Disc Medicine by 2.7% in the third quarter. The Manufacturers Life Insurance Company now owns 29,065 shares of the company's stock valued at $1,428,000 after acquiring an additional 771 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in Disc Medicine by 19.5% during the third quarter. SG Americas Securities LLC now owns 4,864 shares of the company's stock worth $239,000 after acquiring an additional 793 shares during the period. 83.70% of the stock is owned by institutional investors.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.